Phillip B Hylemon Selected Research

HIV Protease Inhibitors

1/2014	Reduction of the HIV protease inhibitor-induced ER stress and inflammatory response by raltegravir in macrophages.
3/2013	The role of CCAAT enhancer-binding protein homologous protein in human immunodeficiency virus protease-inhibitor-induced hepatic lipotoxicity in mice.
1/2013	HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytes.
1/2013	Inhibition of P-glycoprotein by HIV protease inhibitors increases intracellular accumulation of berberine in murine and human macrophages.
8/2010	Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.
2/2010	Berberine inhibits HIV protease inhibitor-induced inflammatory response by modulating ER stress signaling pathways in murine macrophages.
7/2009	HIV protease inhibitor lopinavir-induced TNF-alpha and IL-6 expression is coupled to the unfolded protein response and ERK signaling pathways in macrophages.
11/2007	HIV protease inhibitors increase TNF-alpha and IL-6 expression in macrophages: involvement of the RNA-binding protein HuR.
9/2005	HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Phillip B Hylemon Research Topics

Disease

22	Fibrosis (Cirrhosis) 06/2022 - 01/2013
19	Inflammation (Inflammations) 06/2022 - 11/2002
8	Non-alcoholic Fatty Liver Disease 12/2021 - 06/2008
6	Liver Cirrhosis (Hepatic Cirrhosis) 06/2022 - 01/2017
6	Dysbiosis 12/2021 - 01/2015
5	Cholestasis 06/2022 - 09/2014
5	Liver Diseases (Liver Disease) 06/2022 - 01/2015
5	Infections 12/2019 - 01/2005
5	Cholangiocarcinoma 01/2018 - 08/2014
5	Neoplasms (Cancer) 01/2017 - 01/2008
4	Disease Progression 10/2021 - 01/2015
4	Fistula 04/2015 - 04/2002
4	HIV Infections (HIV Infection) 01/2014 - 02/2010
4	Atherosclerosis 07/2009 - 11/2002
4	Colonic Neoplasms (Colon Cancer) 03/2006 - 05/2003
3	Neuroinflammatory Diseases 01/2021 - 10/2016
3	Hepatic Encephalopathy 08/2016 - 01/2013
3	Endotoxemia 08/2016 - 01/2013
3	Hyperlipidemias (Hyperlipidemia) 02/2015 - 01/2004
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2013 - 09/2005
2	Digestive System Diseases 06/2022 - 01/2016
2	Insulin Resistance 12/2020 - 08/2014
2	Alcoholic Liver Diseases (Alcoholic Liver Disease) 01/2019 - 01/2018
2	Hyperammonemia 01/2016 - 09/2015
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2015 - 11/2007
2	End Stage Liver Disease 09/2012 - 01/2012
2	Dyslipidemias (Dyslipidemia) 08/2010 - 02/2010
1	Fatty Liver 12/2021
1	Acute Liver Failure (Fulminant Hepatic Failure) 11/2021
1	Diabetes Mellitus 01/2021
1	Metabolic Diseases (Metabolic Disease) 01/2021
1	Sclerosing Cholangitis 11/2020
1	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 11/2020
1	Biliary Atresia 11/2019
1	Adenocarcinoma 01/2018
1	Barrett Esophagus (Barrett's Esophagus) 01/2018
1	Hepatitis C 01/2018

Drug/Important Bio-Agent (IBA)

25	Bile Acids and Salts (Bile Acids)IBA 06/2022 - 04/2002
9	HIV Protease InhibitorsIBA 01/2014 - 09/2005
8	Rifaximin (L 105)FDA Link 01/2021 - 01/2012
5	BerberineIBA 12/2021 - 02/2010
5	CholesterolIBA 12/2021 - 11/2002
5	Sphingosine-1-Phosphate ReceptorsIBA 12/2021 - 09/2014
5	Long Noncoding RNAIBA 01/2021 - 10/2019
5	Taurocholic Acid (Sodium Taurocholate)IBA 01/2018 - 08/2010
4	Anti-Bacterial Agents (Antibiotics)IBA 06/2022 - 01/2015
4	AmmoniaIBA 01/2021 - 08/2016
4	LipidsIBA 01/2021 - 09/2005
4	Messenger RNA (mRNA)IBA 01/2019 - 04/2002
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 06/2006
3	Interleukin-6 (Interleukin 6)IBA 12/2019 - 09/2012
3	Lactulose (Duphalac)FDA LinkGeneric 10/2018 - 01/2012
3	Small Interfering RNA (siRNA)IBA 01/2017 - 01/2017
3	Glutamine (L-Glutamine)FDA Link 10/2016 - 01/2016
2	Insulin (Novolin)FDA Link 01/2021 - 05/2020
2	AMP-Activated Protein KinasesIBA 01/2021 - 01/2017
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2021 - 11/2012
2	Nonesterified Fatty Acids (NEFA)IBA 01/2020 - 06/2008
2	gamma-Aminobutyric Acid (GABA)IBA 01/2020 - 01/2019
2	sphingosine kinaseIBA 01/2019 - 04/2015
2	Proton Pump InhibitorsIBA 01/2018 - 11/2014
2	Omeprazole (Prilosec)FDA LinkGeneric 01/2018 - 11/2014
2	Estrogens (Estrogen)FDA Link 01/2017 - 01/2017
2	Cadherins (E-Cadherin)IBA 01/2017 - 08/2016
2	CytokinesIBA 12/2016 - 10/2015
2	GlutaminaseIBA 10/2016 - 08/2016
2	Protease Inhibitors (Protease Inhibitor)IBA 01/2004 - 11/2002
1	Vancomycin FDA LinkGeneric 06/2022
1	High Fructose Corn SyrupIBA 12/2021
1	FatsIBA 12/2021
1	Acetaminophen (Paracetamol)FDA LinkGeneric 11/2021
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 10/2021
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 10/2021
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2021
1	UreaseIBA 01/2021
1	Glucose (Dextrose)FDA LinkGeneric 01/2021
1	CalciumIBA 01/2021
1	FructoseIBA 01/2021
1	Biological FactorsIBA 12/2020
1	OxysterolsIBA 12/2020
1	steroidogenic acute regulatory proteinIBA 12/2020
1	CarbohydratesIBA 05/2020
1	isoquinolineIBA 01/2020
1	AlkaloidsIBA 01/2020
1	16S Ribosomal RNAIBA 01/2020
1	lipopolysaccharide-binding proteinIBA 12/2019
1	Biomarkers (Surrogate Marker)IBA 10/2019
1	N-acetylaspartate (N-acetyl aspartate)IBA 01/2019
1	Ribosomal DNA (rDNA)IBA 01/2018
1	DNA (Deoxyribonucleic Acid)IBA 01/2018
1	Transcription Factor CHOPIBA 01/2018
1	CholatesIBA 01/2018
1	RNA (Ribonucleic Acid)IBA 01/2018
1	Bacterial RNAIBA 01/2018
1	Glycocholic AcidIBA 01/2018

Therapy/Procedure

5	Therapeutics 10/2021 - 11/2014
5	Highly Active Antiretroviral Therapy (HAART) 01/2014 - 09/2005
4	Fecal Microbiota Transplantation 01/2020 - 09/2015
2	Ligation 11/2020 - 01/2018
1	Vagotomy 01/2021